"Tumor development and progression are multi-factorial processes, in which genomic alterations and modifications in gene expression in pre-malignant cells are joined by deleterious micro-environmental factors. The tumor microenvironment contains stroma cel"

The fact that tumors are composed of both tumor cells and host cells has long been known. These tumor-associated cells include vascular endothelial cells and pe- cytes, as well as inflammatory cells such as neutrophils, monocytes, macrophages, mast cells and eosinophils, and lymphocytes. The tumor cells also interact with stromal cells and with elements of the tissue extracellular matrix. What has been less appreciated is the role that these cells could have in modulating the growth, invasion, and metastasis of the tumor. Early on, the elements of what we now call the tumor microenvironment were considered to be more or less innocent bysta- ers to the role of the tumor cells as they grew and invaded local sites. Today, there is an increased understanding of the critical role of the tumor microenvironment as dramatically influencing the course of tumor development and dissemination. This volume represents a superb compilation of the latest thoughts and data regarding the role of each essential component of the tumor microenvironment in cancer development and progression. Perhaps, the earliest recognition of the role of nonmalignant cells as cancer re- lators was the recognition that lymphocytes can participate in what was termed “immune surveillance” in the 1960s. Our understanding of tumor immunity has improved markedly since then, and there are now successful clinical studies sh- ing the potential use of immune-based therapies in cancer treatment.

Analysis of multidirectional immunological responses at the tumor site allows forming a new concept of The Tumor Immunoenvironment, which is introduced and discussed in the present book with a particular focus on the role of immune cells in controlling the tumor microenvironment at different stages of cancer development. The main goal of this publication is to provide an overview of the current knowledge on the complex and unique role of the immune system, tumor-associated inflammation and tumor-mediated immunomodulation in cancer progression in a way that allows understanding the logistics of cellular and molecular interactions in the tumor lesions.

Are we satisfied with the rate of drug development? Are we happy with the drugs that come to market? Are we getting our money's worth in spending for basic biomedical research? In Translational Systems Biology, Drs. Yoram Vodovotz and Gary An address these questions by providing a foundational description the barriers facing biomedical research today and the immediate future, and how these barriers could be overcome through the adoption of a robust and scalable approach that will form the underpinning of biomedical research for the future. By using a combination of essays providing the intellectual basis of the Translational Dilemma and reports of examples in the study of inflammation, the content of Translational Systems Biology will remain relevant as technology and knowledge advances bring broad translational applicability to other diseases. Translational systems biology is an integrated, multi-scale, evidence-based approach that combines laboratory, clinical and computational methods with an explicit goal of developing effective means of control of biological processes for improving human health and rapid clinical application. This comprehensive approach to date has been utilized for in silico studies of sepsis, trauma, hemorrhage, and traumatic brain injury, acute liver failure, wound healing, and inflammation. - Provides an explicit, reasoned, and systematic approach to dealing with the challenges of translational science across disciplines - Establishes the case for including computational modeling at all stages of biomedical research and healthcare delivery, from early pre-clinical studies to long-term care, by clearly delineating efficiency and costs saving important to business investment - Guides readers on how to communicate across domains and disciplines, particularly between biologists and computational researchers, to effectively develop multi- and trans-disciplinary research teams

Armadillo Domain Proteins—Advances in Research and Application: 2013 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about ZZZAdditional Research in a concise format. The editors have built Armadillo Domain Proteins—Advances in Research and Application: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about ZZZAdditional Research in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Armadillo Domain Proteins—Advances in Research and Application: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Oncogenes and tumor suppressor genes had been traditionally studied in the context of cell proliferation, differentiation, senescence, and survival, four relatively cell-autonomous processes. Consequently, in the late ’80s-early ’90s, neoplastic growth was described largely as an imbalance between net cell accumulation and loss, brought about through mutations in cancer genes. In the last ten years, a more holistic understanding of cancer has slowly emerged, stressing the importance of interactions between neoplastic and various stromal components: extracellular matrix, basement membranes, fibroblasts, endothelial cells of blood and lymphatic vessels, tumor-infiltrating lymphocytes, etc. The commonly held view is that changes in tumor microenvironment are “soft-wired”, i.e., epigenetic in nature and often reversible. Yet, there exists a large body of evidence suggesting that well-known mutations in cancer genes profoundly affect tumor milieu. In fact, these non-cell-autonomous changes might be one of the primary reasons such mutations are preserved in late-stage tumors.

A new perspective on the link between inflammation and cancer Inflammation is the human body’s normal biological response to threats in the modern world, as well as a defense against the harmful influence of pathogens, the environment, and poor nutrition. But what happens when the inflammatory response is triggered repeatedly and sustained for long periods of time? Cancer and Inflammation Mechanisms: Chemical, Biological, and Clinical Aspects discusses the mechanisms by which chronic inflammation can lead to cancer, the various causative agents, and possible prevention methods. A compilation of the latest information coming out of the various fields of cancer research, this book provides a detailed look at inflammation-related carcinogenesis from the perspective of researchers at the forefront of the field. It takes an interdisciplinary approach to the topic, and provides comprehensive information about the major factors at work in inflammation, cancer, and the intersection of the two conditions. Topics include: A general overview of inflammation-related cancer The biochemistry of inflammation and its effects on DNA Molecular biology and the role of microRNA in carcinogenesis Specific causative agents including oncogenic viruses, asbestos, and nanomaterial Anti-inflammatories, nutraceuticals, and other preventative measures A deeper understanding of the mechanisms behind inflammation-related carcinogenesis can lead to better patient outcomes by improving diagnostics and prevention, as well as altering the approach to treatment. Cancer and Inflammation Mechanisms: Chemical, Biological, and Clinical Aspects provides the knowledge base researchers need to push the field forward.

Increasing evidence suggests that hidden, low-level inflammation may be the number one cause of modern disease. Shilpa Ravella, an expert in nutrition and the gut, explains why our immune systems are turning against us and what we might do about it. 'Controlling inflammation is the key to good health and this beautifully written and researched book is the best way to understand it' TIM SPECTOR, #1 bestselling author of Food for Life 'A beautiful and authoritative dive into one of the most important scientific frontiers of our time' DANIEL M. DAVIS, Professor of Immunology and author of The Beautiful Cure ___ Inflammation is the body's response to injury and foreign microbes. But as our environments and diets have changed, low-level inflammation, simmering quietly and undetected, has been identified behind everything from heart disease and cancer to mysterious autoimmune conditions. Shilpa Ravella is a doctor at the forefront of this field, specialising in gut transplants, nutrition and the microbiome. In A Silent Fire she interweaves the latest research with unusual case studies from her own practice and the history of immunology to explain what we know about this elusive phenomenon. She debunks common myths about 'anti-inflammatory' lifestyles and explains the simple principles by which we can reform our relationship with food and our microbiomes to benefit our health. ___ 'As gripping as a mystery story and as useful as a self-help book' BEE WILSON, author of First Bite 'Compelling, thoughtful and rigorously researched' The Times